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Abstract
Prediction performance of a risk scoring system needs to be carefully assessed before its
adoption in clinical practice. Clinical preventive care often uses risk scores to screen asymp-
tomatic population. The primary clinical interest is to predict the risk of having an event by
a pre-specified future time t0. Prospective accuracy measures such as positive predictive val-
ues have been recommended for evaluating the predictive performance. However, for com-
monly used continuous or ordinal risk score systems, these measures require a subjective cut-
off threshold value that dichotomizes the risk scores. The need for a cut-off value created bar-
riers for practitioners and researchers. In this paper, we propose a threshold-free summary in-
dex of positive predictive values that accommodates time-dependent event status. We develop
a nonparametric estimator and provide an inference procedure for comparing this summary
measure between competing risk scores for censored time to event data. We conduct a simula-
tion study to examine the finite-sample performance of the proposed estimation and inference
procedures. Lastly, we illustrate the use of this measure on a real data example, comparing two
risk score systems for predicting heart failure in childhood cancer survivors.
Censored event time; Positive predictive value; Precision-recall curve; Risk prediction; Screen-
ing; Time-dependent prediction accuracy
1 Introduction
Clinical medicine is facing a paradigm shift from current diagnosis and treatment practices to
prevention through earlier intervention based on risk prediction [1]. Diagnosis and treatment ap-
proaches help individual patients seek relief from their symptoms. However, evidence is mount-
ing that health interventionsmay bemore effective in improving long-term health outcomes when
they target asymptomatic individuals who are predicted to be at high risk for the condition of in-
terest [2, 3]. The condition of interest typically has the following characteristics: 1) its seriousness
may result in a high risk of mortality or significantly affect the quality of life; 2) early detec-
tion/intervention can make a difference in disease prognosis; and importantly but subtly 3) its
event rate is low. A prevention approach to medicine relies on the development of risk scores to
stratify individuals into different risk groups. Early intervention strategies are typically recom-
mended to subjects who are in the high-risk group.
†Dr. Yuan and Dr. Zhou contributed equally to this work.
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In the prevention paradigm, the use of risk scores as population screening tools is increasingly
advocated in clinical practices, e.g. [4]. For example, one systematic review identified forty-six
algorithms that predict the risk of type 2 diabetes [5]. Another study established several risk score
systems to predict congestive heart failure for childhood cancer survivors who are at an elevated
risk due to treatment toxicity [6]. One of the defining characteristics of screening is a low event rate
in the targeted asymptomatic population. Taking the aforementioned two diseases as an example,
the crude prevalence of undiagnosed type 2 diabetes, a common disease, was low at 3.5% in 1987
and 5.7% in 1992 [7], while the cumulative event rate of congestive heart failure by 35 years post
childhood cancer diagnosiswas 4.7% [6]. The event rate is much lower for other notable conditions
such as cancer, multiple sclerosis, AIDS, dementia, COPD and perinatal conditions. A low event
rate and a focus on prevention necessitate the development of screening tools such as risk scores.
Before a risk scoring system is adopted for clinical screening, evaluation of its predictive accu-
racy is critical. The most popular accuracy metric used in the clinical literature is the area under
the receiver operating characteristic (ROC) curve (AUC). The AUC is a summary index of two ac-
curacy metrics - sensitivity and specificity - which are both retrospective metrics. Thus, the AUC
does not reflect the prospective predictive accuracy of risk score systems. Indeed, one influential
article criticized these retrospective metrics as being of little use for clinicians because clinical in-
terest almost always focuses on prediction [8]. In contrast, a prospective accuracy measure, such
as positive predictive value (PPV), can prospectively answer the question: "Can risk scores be
trusted?" Unfortunately, a risk score with high sensitivity and specificity, and thus a high AUC,
can have poor PPV when applied to low-prevalence populations. This limitation is often over-
looked by clinicians and biomedical researchers. Despite its popularity, studies confirm that the
AUC is insensitive in evaluating risk prediction models. For example, including a marker with a
risk ratio of 3.0 showed little improvement on the AUC, while it could shift the predicted 10-year
disease risk for an individual patient from 8% to 24% [9]. This range would result in different
recommendations on follow-up/intervention strategies.
Compared to the AUC, the PPV provides a more appropriate assessment of the prospective
prediction performance of the risk score [10], making the PPV a superior metric for risk score sys-
tems used as screening tools. The PPV is calculated with data from a prospective cohort, where the
risk scores are computed using baseline information and the outcome is followed prospectively.
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Originally, the PPV was defined for a dichotomous test. Moskowitz and Pepe (2004) extended the
definition of PPV for a continuous risk score [10]. Assuming that the higher the risk score, the
greater the individual risk, the PPV is defined as the probability of having the disease when the
risk score value is larger than a given cut-off value z,
PPV(z) = Pr{D = 1 | Z ≥ z} and NPV(z) = Pr{D = 0 | Z < z}, (1)
where D = 1 indicates the presence of the disease, and D = 0 indicates the absence of the disease.
Zheng et al. (2008) further generalized the definition to accommodate the censored event time
outcome [11]. Since the PPV is threshold dependent, as seen in (1), it is often evaluated at either
several fixed specificities or several fixed quantiles of the . Such evaluations allow the comparison
across different risk score systems [10, 12]. The selection of specificities or quantiles can be sub-
jective, and it is possible that different systems could outperform others, depending on the cut-off
points selected [13].
For the above reasons, a threshold-free summary metric for the PPV is needed to facilitate
its clinical usage. Two curves of PPV have been investigated in the literature. Raghavan et al.
(1989) and Zheng et al. (2010) considered a curve of PPV versus quantiles of the risk score [13, 14].
However, they did not provide a summary index of the proposed PPV curve. A second curve is
called the precision-recall (PR) curve, whichwas proposed in the information retrieval community
[14, 15], where precision is equivalent to the PPV and recall is equivalent to the sensitivity. The
relationship of PR and ROC curves and the area under them has been discussed in Davis and
Goadrich [16]. They showed that the PR curve of a risk score system dominates that of another
system if its ROC curve is also dominant. However, such a relationship does not exist for the area
under these two curves [16, 17]. Two recent papers illustrated the advantage of using the area
under the PR curve over the AUC for predicting low prevalence diseases [18, 19]. We refer to the
summary metric for the area under the PR curve as the average positive predictive value (AP) [18].
These previous research on the area under the PR curve have only considered binary outcomes.
However, for many clinical applications, the outcome is time to event.
We make three contributions in the assessment of risk scoring systems for clinical screening.
First, we define a time-dependentAP, APt0 for censored event time outcomes. We propose a robust
nonparametric estimator of APt0 without modeling assumptions on the relationship between the
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risk score and event time. Secondly, we provide a statistical inference procedure to compare the
APt0 two risks scores regarding . Thirdly, we provide an R package to implement our method.
The paper is organized as follows. In Section 2, we introduce the definition and interpretation of
APt0 . In Section 3, we present the inference procedures for estimating APt0 of a single risk score as
well as the comparison between two competing risk scores. In Section 4, we conduct a simulation
study to investigate the performance of the proposed estimation and inference procedures in finite
samples. In Section 5, we illustrate the proposed metric APt0 by analyzing two risk score systems
with data from the Childhood Cancer Survival Study [20]. We conclude with a discussion and
suggestions for future work in Section 6.
2 Time-dependent Average Positive Predictive Values
Consider a continuous risk score Z. Let T be the time to the event of interest. Time-dependent
PPV and TPF [11, 21] are defined as
PPVt0(z) = Pr{T < t0 | Z ≥ z} and TPFt0(z) = Pr{Z ≥ z | T < t0}. (2)
In the above setting, the event status is time-dependent, i.e., Dt0 = I(T < t0), where I(·) is an
identity function. Consequently, the PPV and TPF are also functions of t0.
Following [18], we defineAPt0 , as the area under the time-dependent PR curve {(TPFt0(z), PPVt0(z)), z ∈
R},
APt0 =
∫
R
PPVt0(z)dTPFt0(z). (3)
Note that the TPF describes the distribution function of Z in “cases" who experience the event
by time t0, i.e. T < t0. It can be shown that APt0 = EZ1 {PPVt0(Z1)}, where Z1 denotes the risk
score in cases. In the real data example of Section 5, we will show that AP is estimated to be 0.114
at t0 = 35 years for a risk score system. That is, by 35 years post diagnosis, we expect that on
average 11.4% of the subjects with a high risk score (compared to the risk score of a randomly
selected case) will experience the event of interest.
In addition, PPVt0(z) can be written as PPVt0(z) = P(Z ≥ z | T < t0)P(T < t0)/P(Z ≥ z) =
πt0 {1− F1(z)} / {1− F(z)}, where F1(z) = Pr(Z < z | T < t0) = P(Z1 < z) is the distribution
function of the risk score Z1 for cases, F(z) = P(Z < z) is the distribution function of the risk
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score Z for the target population, and πt0 = Pr(T < t0) is the event rate by time t0 in the target
population. Thus, the AP can be written as
APt0 = πt0
∫
R
1− F1(z)
1− F(z)
dF1(z). (4)
A perfect risk score system would always assign higher values to cases, individuals with T < t0,
compared to those controls, individuals with T ≥ t0, i.e. P(Z ≥ Z1 | T ≥ t0) = 0. This leads
to APt0 = 1 from equation (4). A non-informative risk score system would randomly assign risk
scores to both cases and controls. i.e., P(Z ≥ z | T ≥ t0) = P(Z ≥ z | T < t0) for each z, which
leads to APt0 = πt0 . Thus, the theoretical range of APt0 is [πt0 , 1].
3 Estimating and Comparing APt0
3.1 Nonparametric Estimator of APt0 for a single risk score
Often, the event times of some subjects are censored due to the end of the study or loss to
follow up. Due to censoring, one can only observe X = min{T,C} where C is the censoring time,
and δ = I(T < C). Let {(Xi, δi,Zi), i = 1, · · · , n} be n independent realizations of (X, δ,Z).
In the presence of censoring, event status at t0, I(Ti < t0), may not be observed for some sub-
jects. We suggest using the inverse probability weighting (IPW) [22, 23] to account for censoring.
The time-dependent PPV and TPF are estimated by
P̂PVt0(z) =
∑
n
i=1 ŵt0,i I(Zi ≥ z)I(Xi < t0)
∑
n
i=1 I(Zi ≥ z)
and T̂PFt0(z) =
∑
n
i=1 ŵt0,i I(Zi ≥ z)I(Xi < t0)
∑
n
i=1 ŵt0,i I(Xi < t0)
,
where ŵt0,i is the inverse of the estimated probability that the time-dependent event status I(Ti <
t0) is observed, specifically
ŵt0,i =
I(Xi < t0)δi
Ĝ(Xi)
+
I(Xi ≥ t0)
Ĝ(t0)
,
where Ĝ(c) is a consistent estimator of the survival function of the censoring time, G(c) = Pr(C ≥
c). Note that the proposed estimator does not imposes any assumptions on the relationship be-
tween the risk score Z and the event time T. Under the assumption of independent censoring,
i.e., the censoring time C is independent of both the event time T and the risk score Z, G(c) can
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be obtained by the nonparametric Nelson-Aalen or Kaplan-Meier estimator. If the censoring time
C depends on the risk score Z, additional model assumptions might be required. For example, a
proportional hazards (PH) model could be fit to estimate Gz(t) = Pr(C ≥ c | Z = z).
Based on the estimated PPVt0(z) and TPFt0(z), APt0 can be estimated by
ÂPt0 =
∑
n
j=1 I(Xj ≤ t0)wˆt0,jP̂PVt0(Zj)
∑
n
j=1 I(Xj ≤ t0)wˆt0,j
. (5)
[22] shows that P̂PVt0(z) and T̂PFt0(z) are both consistent estimators, and thus, ÂPt0 is also a
consistent estimator of APt0 for any given value of t0.
In practice, we often deal with discrete risk scores, where tied risk scores are common. To
accommodate risk scores with ties, following [24], we modify the above estimator (5) by replacing
P̂PVt0(Zj) with
P˜PVt0(Zj) =
∑
n
i=1 ŵt0,i
{
I(Zi > Zj) +
1
2 I(Zi = Zj)
}
I(Xi < t0)
∑
n
i=1
{
I(Zi > Zj) +
1
2 I(Zi = Zj)
} .
To construct confidence intervals, we suggest the nonparametric bootstrap [25] method. Specif-
ically, let ÂP
B
t0
=
{
ÂP
b
t0
, b = 1, 2, · · · , B
}
denote the estimated APt0 obtained from B bootstrape
resamples. A 95% confidence interval (CI) for the APt0 is given as (ÂP
B,0.025
t0 , ÂP
B,0.975
t0 ), where
ÂP
B,0.025
t0 and ÂP
B,0.975
t0 are the 2.5% and 97.5% empirical percentiles of the ÂP
B
t0 , respectively.
3.2 Comparing two risk scores
We consider comparing two risk scores Z1 and Z2 on the APt0 scale. In many studies, both
risk scores Z1 and Z2 are calculated for each individual. With the paired data, we can quantify the
relative predictive performance of Z1 vs. Z2, using the ratio of their respective time-dependent
AP,
rAPt0 = APZ1 ,t0/APZ2 ,t0 ,
where APZ1 ,t0 and APZ2,t0 denote the time-dependent AP for Z1 and Z2 at t0 respectively. For a
single risk score Z, the ratio APZ,t0/πt0 can be regarded as the relative predictive performance of
Z compared to a non-informative risk score.
The AP ratio rAPt0 can be estimated by r̂APt0 = ÂPZ1,t0/ÂPZ2,t0 , where ÂPZ1,t0 and ÂPZ2,t0 are
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the the nonparametric estimator ÂPt0 in (5) of Z1 and Z2 respectively. The standard percentile
bootstrap method descried in Section 3.1 can be used to construct a CI for rAPt0 or test H0 :
rAPt0 = 1 for any given time point t0. Specifically, the CI could be obtained based on the empirical
percentiles of the B bootstrap counterparts of of r̂APt0 , denoted by r̂AP
b
t0
= ÂP
b
Z1,t0
/ÂP
b
Z2,t0
, where
ÂP
b
Z1,t0
and ÂP
b
Z2,t0 are the estimated APt0 for Z1 and Z2 based on the same bootstrap resample,
b = 1, · · · , B.
4 Simulation study
We conducted a simulation study to examine the performance of the time-dependent AP esti-
mator in finite samples. In this simulation study, we considered two risk scores U1 and U2. They
were generated from a standard normal distribution N(0, 1). The event time associated with both
risk scores for the ith subject was generated from the following model
log(Ti) = 7.2− 1.1Ui1 − 2.5Ui2 − 1.5log(U
2
i1) + ǫT,
where ǫT ∼ N(0, 1.5). This setting provides an example where the ROC curves of the two risk
scores cross at time t0 = 8, shown in Figure 1, with AUCU1,t0 and AUCU2,t0 are similar in values.
On the other hand, the PR curve of U1 dominates that of U2 over the most range of the TPR with
APt0 of U1 greater than that of U2.
The censoring time Ci was generated following Ci = min(Ai, Bi+ 1)where, Ai ∼ Uni f orm(0, 50),
and Bi ∼ Gamma(25, 0.75). This configuration results in about 50% of censoring overall. Let
Xi = min(Ti,Ci), δi = I(Ti ≤ Ci). In this setting, the censoring time is independent of both the
event time and risk scores.
We considered three prediction time points t0 where the corresponding event rates are, r =
P(Ti < t0), 0.01, 0.05 and 0.1, respectively. To allow a reasonable number of events by t0, we
generated the data {(Xi, δi,U1i,U2i), i = 1, ..., n} with sample size n being 2000 and 5000 (Tables 1
and 2). In each table, we report the following summary statistics based on 1000 repetitions: bias,
empirical standard error (ESE) of the estimator, average standard errors from bootstrap (ASEb),
and the empirical coverage probability (ECOVPb) of 95% confidence intervals obtained from 1000
bootstrap resamples as described in Section 3.
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Figure 1: The ROC curves in the left panel and the precision-recall curves in the right panel for
the two risk scores U1 and U2 at t0 = 8 when the event rate is 5%. The numbers shown in graph
correspond to the AUC and the AP values.
These results show that the estimators of both time-dependent AP and ratio of AP, AP1/AP2,
between the two risk scores had small biases in all t0 values and different sample sizes. The
bias decreases with increasing event rate and increasing sample size. Also, the standard errors
ASEb obtained from bootstrap were close to the empirical standard errors. Thus, the confidence
intervals attained the nominal coverage probabilities for both smaller sample size 2000 and larger
sample size 5000.
We remark that this simulation provides an illustrative example of the relationship between
ROC curve and PR curve as well as the relationship between the AUC and the AP investigated
in [16]. When the ROC curves of two competing risk scores cross, the PR curves cross too. In
situations like this, the AUC and the AP may rank the risk scores differently. In our simulation
setting,U2 outperformsU1 according to the AUC, which indicates that U2 is better at discriminat-
ing between cases and controls. On the other hand, U1 outperformsU2 according to the AP, which
suggests that U1 is a better screening tool for stratifying subjects into different risk groups.
5 Data Analysis
In this section, we illustrate the use of APt0 metric with a data set from the Childhood Cancer
Survivor Study [20]. This cohort follows children who were initially treated for cancer at 26 US
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Table 1: Results of simulation with sample size 2000.
t0 Event rate TRUE BIAS ESE ASE
b ECOVPb(%)
0.5 0.0101 AP1 0.182 0.0365 0.0810 0.0795 92.3
AP2 0.124 0.0339 0.0689 0.0678 93.0
rAP 1.47 0.4890 1.5300 1.7600 95.1
8 0.0495 AP1 0.364 0.0096 0.0527 0.0516 92.5
AP2 0.266 0.0129 0.0452 0.0450 93.4
rAP 1.37 0.0140 0.3290 0.3320 95.7
36 0.0991 AP1 0.462 0.0098 0.0534 0.0558 95.9
AP2 0.375 0.0118 0.0493 0.0501 94.5
rAP 1.23 0.0135 0.2310 0.2420 94.9
Table 2: Results of simulation with sample size 5000.
t0 Event rate TRUE BIAS ESE ASE
b ECOVPb(%)
0.5 0.0101 AP1 0.182 0.0185 0.0500 0.0504 93.1
AP2 0.124 0.0155 0.0416 0.0417 94.8
rAP 1.47 0.1550 0.7060 0.7600 93.8
8 0.0495 AP1 0.364 0.0042 0.0337 0.0333 92.9
AP2 0.266 0.0049 0.0291 0.0288 93.7
rAP 1.37 0.0060 0.2160 0.2100 95.4
36 0.0991 AP1 0.462 0.0034 0.0354 0.0346 95.5
AP2 0.375 0.0037 0.0310 0.0313 94.1
rAP 1.23 0.0051 0.1490 0.1510 95.0
and Canada institutions between 1970 and 1986 and who survived at least 5 years after their
cancer diagnosis. Among the survivors, cardiovascular disease has been recognized as a leading
contributor to morbidity and mortality [26]. To inform future screening and intervention strategy
for congestive heart failure (CHF) in this population, [6] developed several risk score systems
using the CCSS data and validated them on external cohorts. For the purpose of illustration, we
chose two of these risk scores and evaluated their predictive performance using the proposed
APt0 .
We included 11,457 subjects in our analysis from the CCSS study who met the original study
inclusion criteria and had both risk scores. In this data, a total of 248 subjects experienced the
CHF. Between the two risk scoring systemswe focused on in this data analysis, the simpler model
used information on age at cancer diagnosis, sex, whether the patient was exposed to chest radio-
therapy, and whether the patient was exposed to a particular chemotherapy agent. We refer to
this model as the simple model. The more elaborate model, known as the heart dose model, in-
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cluded detailed clinical information on the average radiation dose to the heart and the cumulative
dose of the specific chemotherapy agent, along with age at diagnosis and sex. This is an example
where a simple risk score system utilizes minimum treatment information and can be used for
any patient by virtually all clinicians, while the more complex risk score system demands specific
dose information which may not be readily available to clinicians providing long-term follow-up
care. We used the original risk scores of the simple model and the heart dosemodel from the refer-
ence study [6]. Briefly, these scores were constructed via linear combinations of the corresponding
covariates, where the regression coefficients were obtained from Poisson regression models.
Table 3 reports the estimated APt0 with 95% CIs for both the simple model (denoted by APs,t0)
and heart dose model (denoted by APh,t0) at t0 = 20 and 35 years post-diagnosis where the cor-
responding estimated event rates were 1.3% and 4.7% respectively. These two models were com-
pared using the ratio of AP, i.e. rAPt0 = APh,t0/APs,t0 . In addition, we also provided the estimated
time-dependent AUC (AUCt0) at these two time points as well as the difference of AUCs between
these two models ∆AUCt0 = AUCh,t0 − AUCs,t0 . To illustrate the time-varying performance for
each model as well as the comparison between these two models over time, APt0 , AUCt0 , rAPt0
and ∆AUCt0 versus t0 were plotted in Figure 2. Note that we assumed independent censoring in
estimating the AP and the AUC.
The results in Table 3 show that the heart dose model outperforms the simple model at both
time points. For example, the estimated AP20 of the heart dose model is 0.075, which indicates
that by 20 years post-diagnosis, using the risk score from the heart dose model, we expect that on
average 7.5% subjects with a high risk score (compared to the risk score of a randomly selected
case) will experience heart failure. This AP is almost six times of the event rate 1.3%, which
corresponds to the AP of a non-informative risk score system. In contrast, the estimated AP20 for
the simple model is 0.039, roughly half of that of the heart dose model (rAP20=1.96, 95%CI:1.41-
2.88). At 35 years post diagnosis, the heart dose model is significantly better than the simple
model with rAP35 = 1.45 (95%CI: 1.26 - 1.70). Indeed, The plots (c) and (d) in Figure 2 show that in
terms of the APt0 , the heart dose model outperforms the simple model at identifying the high risk
subjects from the targeted population at all time points considered. On the other hand, the AUCs
are similar between these two models, as seen in plot (d). Especially, ∆AUC is not significantly
different from 0 at the beginning and towards the end of the time period that were considered,
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For example ∆AUC35 = 0.01 (95% CI: -0.02 - 0.03, p=0.47), shown in Table 3. It suggests that
according to the AUC, there is not much performance difference between the two models. If, due
to incorporating more information, the heart dose model is indeed superior to the simple model
in terms of identifying the high risk individuals, the results in Table 3 and Figure 2 implies that
the AP is a better metric for discriminates the risk prediction performance than the AUC does.
Table 3: Estimated APt0 and AUCt0 with 95% CIs for two risk scoring systems at t0 = 20 and 35
years, respectively. The comparison of APs is measured by rAP and the comparison of AUCs is
measured by ∆AUC.
t0 Event rate Risk score system AP AUC
20 years 0.013 Simple 0.039 (0.029, 0.052) 0.79 (0.75, 0.82)
Heart dose 0.077 (0.050, 0.127) 0.82 (0.78, 0.86)
Comparison 1.96 (1.41, 2.88) 0.03 (0.01, 0.05)
35 years 0.047 Simple 0.079 (0.066, 0.095) 0.81 (0.78, 0.84)
Heart dose 0.114 (0.092, 0.144) 0.82 (0.78, 0.85)
Comparison 1.45 (1.26, 1.70) 0.01 (-0.02, 0.03)
6 Discussion
One of the main goals of clinical risk prediction is to screen the asymptomatic population and
to stratify them for tailored intervention. Prospective accuracy measures such as PPVt0 is preferred
for this purpose. However, the calculation of PPVt0 demands a threshold for continuous risk
scores, which can create practical difficulties for evaluating risk score systems, especially when
more than two systems are compared. In this paper, we defined and interpreted APt0 , which
is the area under the time-dependent precision-recall curve, for event time data. We proposed
a nonparametric estimator of APt0 and a ratio estimator of APt0 for comparing two competing
risk score systems. We suggested the use of the bootstrap method for inference, which is broadly
applicable in practical settings. We also developed an R package APtools for download available
in CRAN which implements our method for binary and survival outcomes.
The AUC has been the most widely used performance metric in the clinical research commu-
nity. A number of authors have pointed out that the AUC is informative on the classification
performance and discrimination power [27, 11, 18], but not an appropriate metric for assessing
the prospective accuracy performance [10, 11]. Consistent with the criticism on the insensitivity
12
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Figure 2: CCSS Data analysis: panel (a) shows the estimates of the time-dependent AP for the sim-
ple model APs,t0 and heart dosemodel APh,t0 ; panel (b) shows the estimates of the time-dependent
AUC for the simple model AUCs,t0 and heart dose model AUCh,t0 ; panel (c) shows the estimates
of rAPt0 = APh,t0/APs,t0 , the ratio of the time-dependent AP of the heart dose model over that of
the simple model; panel (d) shows the estimates of ∆AUCt0 = AUCh,t0 −AUCs,t0 , the difference of
the time-dependent AUC between the heart dose model and the simple model. The dotted lines
in panels (c) and (d) represent the pointwise 95%CI for rAPt0 and ∆AUCt0 , respectively.
of the AUC in evaluating risk prediction models (See [9]), our data analysis illustrated that using
the AUC as the metric, the performance of the simple model and the heart dose model appears
close. However,based on the AP, the heart dose model outperforms the simple model and could
be preferred in clinical screening. Thus the conclusion reached based on the AUC in this example
may mislead researchers and clinicians.
It should be noted that when comparing different risk score systems, the ranking of their AUCs
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and APs are not necessarily concordant; our simulation study in Section 4 gives such an example.
As the purpose of this article is to introduce a time-dependent APt0 , we refer readers to [16] for
insight on the relationship between the ROC curve and PR curve and to [17] where the relationship
between the AUC and the AP is illuminated. Thus, risk scores which perform well in separating
cases from controls may perform poorly in identifying a higher risk subpopulation, which is the
goal of screening. Compared to the AUC, the AP as the summary metric of PPV is better suited in
evaluating the usefulness of the risk scores and comparing the prospective prediction performance
among competing risk scores, when the objective is screening through risk stratification.
[11, 13] proposed to use the curves of PPVt0 versus risk score quantiles as an assessment tool
for quantifying prospective prediction accuracy. One curve corresponds to one particular value
of t0, which limits its ability to assess the accuracy across time points. In contrast, plotting APt0
against time could facilitate visualizing the performance of different risk score systems over time
in one single plot.
Unlike the AUC, the AP is event rate dependent and should be estimated in a prospective
cohort or population-based study. AP cannot be estimated from a case-control study; the estimate
will be of very little use because the prevalence rate is artificially fixed by the study design. While
the range of the AUC is always between 0.5 and 1, the range of AP is between the event rate and
1. While AP’s wide range could be advantageous in differentiating risk score systems, caution is
needed when re-evaluating risk score systems in other study populations for the same outcome.
This is because the underlying event rate may differ among populations. Thus, it is possible that
AP will select different risk score systems as superior for the same outcome in different study
populations.
For future work, we will consider estimating the time-dependent AP with multiple markers,
as well as the incremental value of AP by adding newmarkers on top of an existing risk profile. In
addition, similar to the partial AUC, partial AP could be defined as the area over a certain range
of interest, such as those at the low values of TPF where PPV is typically high. Competing risk in
the context of AP is another topic that needs to be addressed for event time data.
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